Latest News and Press Releases

CLINUVEL has met its recruitment target in its phase III trial (CUV105) of SCENESSE® (afamelanotide 16mg) in vitiligo, with more than 200 patients enrolled

Pioneering biopharmaceutical company CLINUVEL yesterday hosted a wide-ranging market briefing in Dusseldorf, Germany.

CLINUVEL joined an intimate evening at Lady Gaga and Michael Polansky's Malibu home to celebrate the future of photomedicine

UV, HEV protection for individuals at high risk of photoageing and skin cancer MELBOURNE, Australia, March 01, 2023 (GLOBE NEWSWIRE) -- CLINUVEL (ASX: CUV) (Börse Frankfurt: UR9) (ADR Level...

MELBOURNE, Australia, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Executive summaryPositive Results in the Half Year to 31 December 2022 19% increase in revenues from clinical demand for SCENESSE®...

MELBOURNE, Australia, Jan. 16, 2023 (GLOBE NEWSWIRE) -- Results from a clinical trial in a genetic DNA repair disorder show that a new drug – afamelanotide – may be able to reduce the development of...

LONDON, April 29, 2022 (GLOBE NEWSWIRE) --       Dear shareholders, friends, Both from a professional viewpoint and as largest private holder, I have felt the urge to share my uncensored mind on...

MELBOURNE, Australia, Sept. 10, 2020 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD today announced the progression of its drug SCENESSE® (afamelanotide 16mg) to treat the disease xeroderma...

MELBOURNE, Australia and SINGAPORE, Aug. 31, 2020 (GLOBE NEWSWIRE) -- The CLINUVEL Group today announced the opening of its state-of-the-art centralised Research & Development Centre in...

MELBOURNE, Australia and SINGAPORE, July 13, 2020 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS today revealed PRÉNUMBRA®, the Company’s second afamelanotide product in development. PRÉNUMBRA® is a...